Global CD74 Antibody Market Strategic Research Report

The global CD74 antibody market occupies a strategically significant position within the broader oncology and immunology research tools landscape. CD74, a type II transmembrane glycoprotein that serves as the invariant chain of MHC class II molecules and a receptor for macrophage migration inhibitory factor (MIF), has emerged as a validated therapeutic and diagnostic target across multiple hematologic malignancies and autoimmune conditions. The market was valued at approximately 187 million USD in 2024, reflecting sustained demand from pharmaceutical and biopharmaceutical companies conducting targeted therapy development, academic and clinical research institutions pursuing mechanistic immunology studies, and in vitro diagnostics developers incorporating CD74 as a biomarker in companion diagnostic panels. Its expression profile in B-cell lymphomas, multiple myeloma, non-small cell lung cancer, and gastric carcinomas has positioned CD74 antibodies as a high-priority reagent and therapeutic class in oncology pipelines worldwide.

The market's expansion is driven by three converging forces. First, the accelerating clinical development of antibody-drug conjugates (ADCs) targeting CD74 — most notably STRO-001 and milatuzumab-based payloads — has substantially increased demand for high-specificity research-grade and GMP-grade CD74 antibodies used in preclinical validation and manufacturing process development. Second, the growing adoption of multiplexed immunohistochemistry and flow cytometry panels in translational research has elevated the consumption of CD74-specific clones such as LN2 and M-B741, as pathology laboratories integrate CD74 staining into routine B-cell lineage and lymphoma classification workflows. Third, expanding research funding directed toward MIF-CD74 axis inhibition in chronic inflammatory disease — including rheumatoid arthritis and inflammatory bowel disease — has opened a non-oncology demand channel that diversifies the market's revenue base. The primary restraint is the highly specialized and fragmented purchasing behavior characteristic of antibody research tools markets, where individual laboratory budgets are modest, procurement cycles are short, and switching between supplier clones is common, limiting the revenue concentration and pricing power that typically benefit platform-level life science tools businesses.

This report provides a comprehensive, quantitatively grounded analysis of the global CD74 antibody market spanning the 2025–2032 forecast period, with historical context from 2019 through 2024. It covers market segmentation by antibody type, application, and end user, alongside regional and country-level revenue forecasts, competitive profiling of ten major market participants, and structured assessments of drivers, inhibitors, competitive dynamics, and emerging trends. The report is designed for corporate strategy teams evaluating adjacencies in the life science tools sector, investment analysts conducting due diligence on antibody platform companies, M&A advisors assessing consolidation opportunities among research reagent suppliers, and procurement managers benchmarking supplier capabilities and pricing structures within the CD74 antibody supply chain.